Concepedia

Author

Bojana Milojkovic Kerklaan

The Netherlands Cancer Institute

Also Known As

B Milojkovic Kerklaan, B. M. Kerklaan, B. Milojkovic Kerklaan, Bojana Milojkovic Kerklaan

17

Publications

581

Citations

11

H-Index

18

Concepts

All Affiliations

The Netherlands Cancer InstituteUtrecht UniversityInstitut Jules BordetUniversité Libre de BruxellesOncode Institute
BM

About

Bojana Milojkovic Kerklaan is an author at The Netherlands Cancer Institute specializing in radiation oncology, cancer therapeutics, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

132

2

Cancer Therapeutics

5

5

132

3

Pharmacology

4

4

100

4

Neurology

3

3

83

5

Pathology

2

2

46

Bojana Milojkovic Kerklaan

×

10

Publications

539

Citations

10

H-Index

YearCitations

Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer

Annelies H. Boekhout, Jourik A. Gietema, Bojana Milojkovic Kerklaan,

JAMA Oncology

2016

189

EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors

Bojana Milojkovic Kerklaan, Dick Pluim, Mijke Bol,

Neuro-Oncology

2015

72

Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases

Mark T. J. van Bussel, Dick Pluim, Bojana Milojkovic Kerklaan,

Neurology

2020

63

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte,

Investigational New Drugs

2016

60

Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma

Pieter J. Gaillard, Bojana Milojkovic Kerklaan, Philippe Aftimos,

Cancer Research

2014

37

Phase 1/2A Study of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (Bm) from Solid Tumors or Recurrent High Grade Gliomas (Hgg)

Dieta Brandsma, Bojana Milojkovic Kerklaan, Véronique Dièras,

Annals of Oncology

2014

32

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

Bojana Milojkovic Kerklaan, S. Slater, Michael Flynn,

Investigational New Drugs

2016

28

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

Bojana Milojkovic Kerklaan, Martijn P. Lolkema, Lot A. Devriese,

British Journal of Cancer

2015

23

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

Bojana Milojkovic Kerklaan, Véronique Dièras, Christophe Le Tourneau,

Cancer Chemotherapy and Pharmacology

2012

21

NT-23 * PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)

Bojana Milojkovic Kerklaan, Agnes Jager, Philippe Aftimos,

Neuro-Oncology

2014

14

Page 1